{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:27:55Z","timestamp":1790234875408,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A640323"],"award-info":[{"award-number":["N42A640323"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A640323"],"award-info":[{"award-number":["N42A640323"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A640323"],"award-info":[{"award-number":["N42A640323"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-86172-y","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:12:48Z","timestamp":1736554368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Supattra","family":"Hunsuwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3194-1511","authenticated-orcid":false,"given":"Sarinya","family":"Boongird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiporn","family":"Ingsathit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchana","family":"Ponthongmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattawut","family":"Unwanatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"86172_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov, B. et al. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: Asystematic analysis for the global burden of Disease Study 2017. Lancet 395, 709\u2013733. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3 (2020).","journal-title":"Lancet"},{"key":"86172_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrneph201525","volume":"11","author":"CM Rhee","year":"2015","unstructured":"Rhee, C. M., Kovesdy, C. P. & Epidemiology Spotlight on CKD deaths-increasing mortality worldwide. Nat. Rev. Nephrol. 11, 199\u2013200. https:\/\/doi.org\/10.1038\/nrneph201525 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"86172_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/ndt\/gfv466","volume":"31","author":"JW Stanifer","year":"2016","unstructured":"Stanifer, J. W., Muiru, A., Jafar, T. H. & Patel, U. D. Chronic kidney disease in low- and middle-income countries. Nephrol. Dial Transpl. 31, 868\u2013874. https:\/\/doi.org\/10.1093\/ndt\/gfv466 (2016).","journal-title":"Nephrol. Dial Transpl."},{"key":"86172_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","volume":"34","author":"KJ Jager","year":"2019","unstructured":"Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol. Dial Transpl. 34, 1803\u20131805. https:\/\/doi.org\/10.1093\/ndt\/gfz174 (2019).","journal-title":"Nephrol. Dial Transpl."},{"key":"86172_CR5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita, K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: Acollaborative meta-analysis. Lancet 375, 2073\u20132081. https:\/\/doi.org\/10.1016\/s0140-6736(10)60674-5 (2010).","journal-title":"Lancet"},{"key":"86172_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/nejm199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative Study Group. N Engl. J. Med. 329, 1456\u20131462. https:\/\/doi.org\/10.1056\/nejm199311113292004 (1993).","journal-title":"N Engl. J. Med."},{"key":"86172_CR7","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","year":"2024","unstructured":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 105, S117\u2013s314, doi:https:\/\/doi.org\/10.1016\/j.kint.2023.10.018 (2024).","journal-title":"Kidney Int."},{"key":"86172_CR8","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright, J. T. Jr. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: R esults from the AASK trial. JAMA 288, 2421\u20132431. https:\/\/doi.org\/10.1001\/jama.288.19.2421 (2002).","journal-title":"JAMA"},{"key":"86172_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl. J. Med. 345, 851\u2013860. https:\/\/doi.org\/10.1056\/NEJMoa011303 (2001).","journal-title":"N Engl. J. Med."},{"key":"86172_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl. J. Med. 380, 2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744 (2019).","journal-title":"N Engl. J. Med."},{"key":"86172_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington, W. G. et al. Empagliflozin in patients with chronic kidney disease. N Engl. J. Med. 388, 117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233 (2023).","journal-title":"N Engl. J. Med."},{"key":"86172_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N Engl. J. Med. 383, 1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816 (2020).","journal-title":"N Engl. J. Med."},{"key":"86172_CR13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","volume":"42","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink, H. J. L. et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: Apre-specified analysis from the DAPA-CKD randomized controlled trial. Eur. Heart J. 42, 1216\u20131227. https:\/\/doi.org\/10.1093\/eurheartj\/ehab094 (2021).","journal-title":"Eur. Heart J."},{"key":"86172_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): Amultinational observational cohort study. Lancet Diabetes Endocrinol. 8, 27\u201335. https:\/\/doi.org\/10.1016\/s2213-8587(19)30384-5 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"86172_CR15","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.2337\/dc21-1081","volume":"44","author":"H Nagasu","year":"2021","unstructured":"Nagasu, H. et al. Kidney outcomes Associated with SGLT2 inhibitors Versus other glucose-lowering drugs in real-world clinical practice: The Japan chronic kidney Disease Database. Diabetes Care. 44, 2542\u20132551. https:\/\/doi.org\/10.2337\/dc21-1081 (2021).","journal-title":"Diabetes Care"},{"key":"86172_CR16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/ckj\/sfac044","volume":"15","author":"AYL Liu","year":"2022","unstructured":"Liu, A. Y. L. et al. A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clin. Kidney J. 15, 1403\u20131414. https:\/\/doi.org\/10.1093\/ckj\/sfac044 (2022).","journal-title":"Clin. Kidney J."},{"key":"86172_CR17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl. J. Med. 373, 2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720 (2015). Empagliflozin.","journal-title":"N Engl. J. Med."},{"key":"86172_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl. J. Med. 380, 347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389 (2019).","journal-title":"N Engl. J. Med."},{"key":"86172_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen, B. L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: Asystematic review and meta-analysis. Lancet Diabetes Endocrinol. 7, 845\u2013854. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"86172_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/03007995.2017.1320277","volume":"33","author":"J Cai","year":"2017","unstructured":"Cai, J., Divino, V. & Burudpakdee, C. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States. Curr. Med. Res. Opin. 33, 1317\u20131328. https:\/\/doi.org\/10.1080\/03007995.2017.1320277 (2017).","journal-title":"Curr. Med. Res. Opin."},{"key":"86172_CR21","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1111\/dom.15111","volume":"25","author":"AK Forbes","year":"2023","unstructured":"Forbes, A. K. et al. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: Asystematic review and meta-analysis of observational studies. Diabetes Obes. Metab. 25, 2310\u20132330. https:\/\/doi.org\/10.1111\/dom.15111 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"86172_CR22","doi-asserted-by":"publisher","first-page":"1094221","DOI":"10.3389\/fendo.2023.1094221","volume":"14","author":"S Siriyotha","year":"2023","unstructured":"Siriyotha, S. et al. Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial. Front. Endocrinol. (Lausanne). 14, 1094221. https:\/\/doi.org\/10.3389\/fendo.2023.1094221 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"86172_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5551\/jat.3061","volume":"17","author":"JG Yang","year":"2010","unstructured":"Yang, J. G. et al. Chronic kidney disease, all-cause mortality and cardiovascular mortality among Chinese patients with established cardiovascular disease. J. Atheroscler Thromb. 17, 395\u2013401. https:\/\/doi.org\/10.5551\/jat.3061 (2010).","journal-title":"J. Atheroscler Thromb."},{"key":"86172_CR24","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/archinte.167.11.1130","volume":"167","author":"EF Elsayed","year":"2007","unstructured":"Elsayed, E. F. et al. Cardiovascular disease and subsequent kidney disease. Arch. Intern. Med. 167, 1130\u20131136. https:\/\/doi.org\/10.1001\/archinte.167.11.1130 (2007).","journal-title":"Arch. Intern. Med."},{"key":"86172_CR25","doi-asserted-by":"publisher","unstructured":"Singh, A. K. et al. Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials. Eur. Heart J. 43 https:\/\/doi.org\/10.1093\/eurheartj\/ehac544.1053 (2022).","DOI":"10.1093\/eurheartj\/ehac544.1053"},{"key":"86172_CR26","doi-asserted-by":"publisher","first-page":"205435812098537","DOI":"10.1177\/2054358120985375","volume":"8","author":"T Wilson","year":"2021","unstructured":"Wilson, T. et al. Treatment preferences for Cardiac procedures of patients with chronic kidney disease in Acute Coronary Syndrome: design and pilot testing of a Discrete Choice Experiment. Can. J. Kidney Health Dis. 8, 2054358120985375. https:\/\/doi.org\/10.1177\/2054358120985375 (2021).","journal-title":"Can. J. Kidney Health Dis."},{"key":"86172_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin, R. et al. SGLT-2 inhibitors and the risk of infections: Asystematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 55, 503\u2013514. https:\/\/doi.org\/10.1007\/s00592-018-1116-0 (2018).","journal-title":"Acta Diabetol."},{"key":"86172_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl. J. Med. 373, 2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720 (2015).","journal-title":"N Engl. J. Med."},{"key":"86172_CR29","doi-asserted-by":"publisher","first-page":"110200","DOI":"10.1016\/j.diabres.2022.110200","volume":"195","author":"GC Chan","year":"2023","unstructured":"Chan, G. C., Ng, J. K., Chow, K. M. & Szeto, C. C. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: Apopulation-based propensity score-matched cohort study. Diabetes Res. Clin. Pract. 195, 110200. https:\/\/doi.org\/10.1016\/j.diabres.2022.110200 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"86172_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/m18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave, C. V. et al. Sodium-glucose Cotransporter-2 inhibitors and the risk for severe urinary tract infections: APopulation-based Cohort Study. Ann. Intern. Med. 171, 248\u2013256. https:\/\/doi.org\/10.7326\/m18-3136 (2019).","journal-title":"Ann. Intern. Med."},{"key":"86172_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/ckj\/sfz170","volume":"13","author":"PA Sarafidis","year":"2019","unstructured":"Sarafidis, P. A. & Ortiz, A. The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern? Clin. Kidney J. 13, 24\u201326. https:\/\/doi.org\/10.1093\/ckj\/sfz170 (2019).","journal-title":"Clin. Kidney J."},{"key":"86172_CR32","unstructured":"Administration., U. S. F. & a., D. FDA Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About too much Acid in the Blood and Serious Urinary Tract Infections; (2015). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm;published 4 December ; last accessed 24 April 2024., http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm (2015)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86172-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86172-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86172-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T01:02:53Z","timestamp":1736557373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86172-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86172"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86172-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1667"}}